Equity Overview
Price & Market Data
Price: $0.513
Daily Change: -$0.0035 / 0.68%
Daily Range: $0.496 - $0.53
Market Cap: $76,428,559
Daily Volume: 3,889,086
Performance Metrics
1 Week: -6.79%
1 Month: -22.83%
3 Months: -42.01%
6 Months: -34.30%
1 Year: -51.11%
YTD: -48.38%
Company Details
Employees: 152
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.